Department of Perioperative Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France.
iGReD, CNRS, INSERM, Université Clermont Auvergne, Clermont-Ferrand, France.
PLoS One. 2022 Dec 29;17(12):e0278090. doi: 10.1371/journal.pone.0278090. eCollection 2022.
The COVID-19 pandemic has increased the number of patients in ICUs leading to a worldwide shortage of the intravenous sedative agents obligating physicians to find alternatives including inhaled sedation. Inhaled sedation in French ICU has been previously explored in 2019 (VOL'ICU study). This survey was designed to explore the use of inhaled sedation two years after our first survey and to evaluate how the COVID-19 pandemic has impacted the use of inhaled sedation.
We designed a national survey, contacting medical directors of French ICUs between June and October 2021. Over a 50-item questionnaire, the survey covered the characteristics of the ICU, data on inhaled sedation, and practical aspects of inhaled ICU sedation for both COVID-19 and non-COVID-19 patients. Answers were compared with the previous survey, VOL'ICU.
Among the 405 ICUs contacted, 25% of the questionnaires were recorded. Most ICU directors (87%) knew about the use of inhaled ICU sedation and 63% of them have an inhaled sedation's device in their unit. The COVID-19 pandemic increased the use of inhaled sedation in French ICUs. The main reasons said by the respondent were "need for additional sedative" (62%), "shortage of intravenous sedatives" (38%) and "involved in a clinical trial" (30%). The main reasons for not using inhaled ICU sedation were "device not available" (76%), "lack of familiarity" (60%) and "no training for the teams" (58%). More than 70% of respondents were overall satisfied with the use of inhaled sedation. Almost 80% of respondents stated that inhaled sedation was a seducing alternative to intravenous sedation for management of COVID-19 patients.
The use of inhaled sedation in ICU has increased fastly in the last 2 years, and is frequently associated with a good satisfaction among the users. Even if the COVID-19 pandemic could have impacted the widespread use of inhaled sedation, it represents an alternative to intravenous sedation for more and more physicians.
COVID-19 大流行导致 ICU 患者数量增加，导致全球静脉镇静剂短缺，迫使医生寻找替代品，包括吸入镇静剂。2019 年，法国 ICU 曾对吸入镇静进行过研究（VOL'ICU 研究）。本调查旨在探讨我们首次调查两年后吸入镇静的使用情况，并评估 COVID-19 大流行如何影响吸入镇静的使用。
我们设计了一项全国性调查，在 2021 年 6 月至 10 月期间联系了法国 ICU 的医疗主任。在 50 多项问卷调查中，调查涵盖了 ICU 的特点、吸入镇静的数据以及 COVID-19 和非 COVID-19 患者吸入 ICU 镇静的实际方面。答案与之前的调查（VOL'ICU）进行了比较。
在联系的 405 家 ICU 中，有 25%的问卷被记录。大多数 ICU 主任（87%）了解吸入 ICU 镇静的使用情况，其中 63%的单位有吸入镇静设备。COVID-19 大流行增加了法国 ICU 中吸入镇静的使用。受访者表示使用吸入镇静的主要原因是“需要额外的镇静剂”（62%）、“静脉镇静剂短缺”（38%）和“参与临床试验”（30%）。不使用吸入 ICU 镇静的主要原因是“设备不可用”（76%）、“缺乏熟悉度”（60%）和“未对团队进行培训”（58%）。超过 70%的受访者对吸入镇静的使用总体满意。近 80%的受访者表示，吸入镇静是管理 COVID-19 患者时替代静脉镇静的诱人选择。
在过去的 2 年中，ICU 中吸入镇静的使用迅速增加，并且经常得到使用者的高度满意。即使 COVID-19 大流行可能影响了吸入镇静的广泛使用，但它代表了越来越多医生的静脉镇静替代方案。
